
Austria: A Hotspot for Life Sciences
An Attractive and Highly Sought-after Business Location
The life sciences sector, encompassing biotechnology, pharmaceuticals and medical technology, is developing rapidly in Austria.
An Attractive and Highly Sought-after Business Location
The life sciences sector, encompassing biotechnology, pharmaceuticals and medical technology, is developing rapidly in Austria.
Technological developments in the pharmaceutical and biotech industry are reflected in increased funding, higher R&D productivity and more product launches. However, the general conditions remain challenging. Incremental change won’t be enough to deliver the results that the market and patients demand, warn industry experts.
The top management of life sciences companies is very optimistic about 2024 and 2025, with over 80% of pharmaceutical, medical technology and biotechnology executives expecting profit growth for the current year and over 90% for the coming year. Around one in two companies expect profits to rise by more than 5% this year and 70% next year. These are the findings of the annual survey "Life Sciences Executives Flash Report" by consulting company Horváth.
Fluor Corporation announced today that it has completed construction of Bayer’s first global Cell Therapy Launch Facility in Berkeley, California. Completion was celebrated on October 10, 2023, at the new facility with local officials, dignitaries, Bayer employees, and clients.
US science and technology group Danaher has entered into a definitive agreement to acquire Abcam, a supplier of life science research tools. Danaher will buy all of the outstanding shares of Abcam for $24.00 per share. The transaction, which is worth about $5.7 billion, is expected to close in mid-2024.
Fluor has been awarded a €444 million ($487 million) biotech expansion project in Denmark and is in the first phase of a new life sciences production facility in the US valued at €523 million ($574 million). The two contracts will be recognized in the Q2 backlog.
India-headquartered drugmaker Glenmark is said to be taking another look at selling a majority stake in its business with active pharmaceutical ingredients (APIs), which is wrapped up in subsidiary Glenmark Life Sciences.
German chemicals, pharmaceuticals and life sciences group Merck and US semiconductors giant Intel have signed a letter of intent to fund a European academic research program that will leverage artificial intelligence (AI) and machine learning technologies to drive innovation.
The consolidation in the distribution sector continues. In the latest deal, Life Sciences distributor Barentz International has announced the acquisition of Volp Indústria e Comércio, a Brazilian distributor of supplies and solutions for the Personal Care sector.
Azelis has agreed to acquire a majority stake in ROCSA Colombia, a specialty chemical distributor serving the life sciences and industrial chemical markets in South America.